First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report - Top-Institutions - MDSpire

First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report

  • By

  • Andreas Holstein

  • Ingy Jabri

  • Jonas A. Linck

  • Anke Tönjes

  • David J. F. Holstein

  • Peter Kovacs

  • Luise Pirlich

  • June 22, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    UT Southwestern Medical Center
    UT Southwestern Medical Center

    Dallas, Texas

    Key Differentiators

    • Endocrinology

  • #2

    National Institutes of Health (NIH)—NIDDK/NIH Clinical Center
    National Institutes of Health (NIH)—NIDDK/NIH Clinical Center

    Bethesda, Maryland

    Key Differentiators

    • Endocrinology

  • #3

    Malmö Diet and Cancer
    Malmö Diet and Cancer

    Malmö, Sweden

    Key Differentiators

    • Endocrinology

  • #4

    Malmö Preventive Project
    Malmö Preventive Project

    Malmö, Sweden

    Key Differentiators

    • Endocrinology

  • #5

    UK Biobank
    UK Biobank

    Stockport, England

    Key Differentiators

    • Endocrinology

Original Source(s)

First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report

  • by Andreas Holstein, Ingy Jabri, Jonas A. Linck, Anke Tönjes, David J. F. Holstein, Peter Kovacs, Luise Pirlich

  • June 22, 2026

Related Content

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Gut microbiome dysbiosis in PCOS: from pathogenesis to microbiome-targeted therapies

Supreme Court extends mifepristone deadline